Exscientia raises $60 million in Series C financing round led by Novo Holdings

26th May 2020, Oxford, Copenhagen, and Hamburg – Exscientia, the world leading artificial intelligence (AI) drug discovery company, today announced it has raised $60 million in a Series C financing round. The financing round has been led by new investor Novo Holdings with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital (through its LPs) – participating in the round. Robert Ghenchev, Senior Partner and Head of Novo Growth, the growth equity arm of Novo Holdings, joins Exscientia’s board of directors as part of the financing round.

More ›

RefleXion Medical raises $100m for biology-guided cancer radiotherapy

Public Sector Pension Investment Board (PSP Investments), a large, Canada-based pension investment manager focused on long-term investments, led the funding, according to a news release. Existing investors TPG’s The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc. all participated in the round. BofA Securities and Morgan Stanley acted as placement agents.

More ›

Celgene has joined forces with Exscientia for a three-year collaborat

Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program. In addition, Exscientia is due to receive tiered royalties on net sales on any product resulting from the collaboration. Exscientia will apply its full-stack AI drug discovery capabilities to the execution of the entire project – from gene to the drug candidate.

More ›

Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic

Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its development program, the investigation of tebentafusp (IMCgp100) for the treatment of patients who are HLA-A*0201-positive with previously untreated, metastatic uveal melanoma (mUM).

More ›